Aspect Biosystems Deepens Novo Nordisk Alliance to Advance Curative Cell Therapies for Diabetes | iPharmaCenter
- ipharmaservices
- 6 days ago
- 2 min read
Aspect Biosystems and Novo Nordisk have agreed to expand and reshape their existing collaboration to accelerate the development of cell‑based therapies intended to transform the treatment of diabetes. The updated agreement marks a move into a new phase of the partnership, with Aspect assuming broader control of core programmes and Novo Nordisk contributing additional technologies, capabilities and funding.
The companies have been working together since 2023 on engineered cellular therapies designed to restore, replace or augment impaired biological functions in chronic metabolic disease. Building on progress in the initial collaboration, the new framework is intended to speed the path toward therapies with curative potential for people living with serious conditions such as type 1 diabetes.
Under the revised deal, Aspect has obtained rights to stem cell‑derived islet cell technologies and hypoimmune cell engineering platforms originating from Novo Nordisk. Aspect will now take the lead on research, development, manufacturing and commercialisation of resulting product candidates, while Novo Nordisk retains clearly defined options to increase its involvement in late‑stage development and commercial execution at a future point.
Novo Nordisk will support this next phase through an additional equity investment in Aspect Biosystems and by providing research funding to drive forward selected programmes. In return, Novo Nordisk will be eligible for milestone payments tied to development and commercial progress, as well as royalties on any future product sales that emerge from Aspect’s pipeline under the partnership.
A key element of the agreement is the planned transfer and integration of select Novo Nordisk cell therapy research, development and manufacturing capabilities from sites in the United States and Denmark into Aspect’s platform, which is anchored in Canada. This consolidation is expected to enhance Aspect’s end‑to‑end infrastructure, broaden access to specialised talent and strengthen its ability to advance complex cell‑based products from discovery through to industrial‑scale production.
Aspect’s technology platform is being applied to create a new generation of cellular medicines aimed at delivering functional cures for metabolic and endocrine disorders. One priority programme focuses on an islet cell replacement therapy for type 1 diabetes that is designed to re‑establish physiological blood glucose regulation without requiring long‑term systemic immunosuppression. The approach is intended to use allogeneic, off‑the‑shelf cells, supporting scalable manufacturing and broad patient access if clinical development is successful.
Comments